Pharming Group announces that an agreement has been reached with the Spanish Ministry of Health to grant reimbursement for RUCONEST® (conestat alfa) in Spain.

Download full press releaseEN
Download volledig persberichtNL

We are delighted with this positive reimbursement decision by the Spanish Ministry of Health, as it means patients in Spain in need of new treatment options for hereditary angioedema will now be able to access RUCONEST®

- Sijmen de Vries - CEO

Attachments

  • Original document
  • Permalink

Disclaimer

Pharming Group NV published this content on 04 June 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 04 June 2021 07:14:03 UTC.